Common Stock, par value $0.0001 per share (common), issuer CIK 2056611
Filings received so far for Q3 2026: 58 13F filers report a position in LTGO shares at 2026-09-30. The quarter is not complete: its 13F deadline is 2026-11-14, and the counts grow as filings arrive.
13D and 13G filers
Each filer's latest stake. The shares are the aggregate the reporting persons state, which can include entities that file no 13F.
AI Biotechnology LLC 3,193,565 shares, 4.8% in a 13G/A as of 2026-09-03,0001193125-26-452089 Accepted , ingested
Insider trades
No Form 4 transaction on this security in the data.
13F holders, Q3 2026
Filers in the available 13F reports with a share position at 2026-09-30, filer groups collapsed to one row (method), largest first. Options and principal amounts are left out. A group row states no % of portfolio, since each member reports its own portfolio: the members' percents are listed under it. A value about 1,000 times or 1/1,000 of the price other filers imply is shown as filed but neither ranks the row nor enters a sum.
5AM Ventures VI, L.P. and 5 other reporting persons reported 7,325,962 LTGO shares, 11% of the class, as of 2026-09-30, in a 13G filed 2026-11-16. 0001753037-26-000010
Accepted , ingested
Blue Owl Capital Holdings LP reported 3,596,780 LTGO shares, 5.43% of the class, as of 2026-09-30, in a 13G filed 2026-11-13. 0001140361-26-043775
Accepted , ingested
AI Biotechnology LLC and 3 other reporting persons reported 3,193,565 LTGO shares, 4.8% of the class, as of 2026-09-03, in a 13G/A filed 2026-11-06. 0001193125-26-452089
Accepted , ingested
Westlake BioPartners Fund I, L.P. and 6 other reporting persons reported 13,199,669 LTGO shares, 19.9% of the class, as of 2026-09-30, in a 13G filed 2026-10-29. 0001104659-26-120296